WELL Health completes acquisition of CRH Medical

On April 23, 2021, WELL Health Technologies Corp. ("WELL") and CRH Medical Corporation ("CRH") announced the successful completion of their previously-announced business combination, pursuant to which WELL acquired all of the issued and outstanding common shares of CRH for US$4.00 per share in cash, representing an equity consideration of approximately US$286.6 million and a transaction value of approximately US$372.9 million, inclusive of CRH's credit facility.

The acquisition, announced February 8, 2021, was carried out by way of a statutory court-approved plan of arrangement under the Business Corporations Act (British Columbia) and funded in part by the proceeds of a concurrently announced C$302.5 million non-brokered equity offering of subscription receipts.

In connection with completion of the transaction, CRH’s shares were delisted from the TSX and their trading suspended on the NYSE American. The shares will be formally delisted from the NYSE American on or about May 3, 2021 and CRH intends to submit an application or other appropriate documents to the applicable securities regulators in Canada and the United States to cease to be a reporting issuer and to terminate its public reporting obligations.

Further information can be found on Canada Newswire’s website.

WELL Health Technologies is an omni-channel digital health company whose overarching objective is to empower doctors to provide the best and most advanced care possible while leveraging the latest trends in digital health.

CRH Medical is a North American company focused on providing gastroenterologists throughout the United States with innovative services and products for the treatment of gastrointestinal diseases.